ArticleJournal of gastrointestinal oncology2026
Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ivermectin suppresses tumor growth in various cancers. However, the mechanism of action in cancer remains unclear. This study aimed to investigate the anticancer activity of ivermectin against gastric cancer cell lines and patient-derived organoids. Methods: Cell viability was measured in SNU719 and SNU620 gastric cancer cell lines. Protein expression levels of apoptosis-related markers were analyzed by western blotting and flow cytometry. The response of primary gastric cancer organoids (GC7 and GC15) to cisplatin and ivermectin treatments was evaluated. The organoids were stained with propidium iodide (PI) and calcein acetoxymethyl ester (AM). Messenger RNA (mRNA) expression levels were analyzed in both cell lines and organoids. Results: Ivermectin suppressed SNU719 cell viability in a dose-dependent manner and enhanced the effect of cisplatin. However, ivermectin showed no significant effect on cell viability in SNU620 cells. Reverse transcription-polymerase chain reaction (RT-PCR) revealed that ivermectin reduced connective tissue growth factor ( Conclusions: Ivermectin showed anticancer effects in both two-dimensional (2D) and three-dimensional (3D) cultures, but differentially regulated anti-apoptotic genes, suppressing them in 2D cultures and increasing them in organoids. These findings suggest that ivermectin transiently suppresses YAP1-related signaling and induces apoptotic cell death at early treatment time points in gastric cancer cells. However, further research is required to assess its therapeutic potential and limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.